Clinical-stage life sciences company ZYUS Life Sciences Corporation (TSXV:ZYUS) on Thursday reported favourable preliminary results from its ongoing Phase 2a UTOPIA-1 (Unique Treatment of Oncology Pain in Advanced Cancer) trial evaluating Trichomylin softgel capsules in patients experiencing moderate to severe cancer-related pain.

UTOPIA-1, a single-arm, proof-of-concept study, is designed to investigate the safety and preliminary analgesic efficacy of Trichomylin softgel capsules in patients with advanced cancer and moderate to severe cancer-related pain.

Preliminary results from the Phase 2a trial are based on data from the first 25% of enrolled patients that have completed treatment in the UTOPIA-1 trial. The company says that early data suggest a reduction in average daily pain, pain interference, and pain severity, and a reduction in opioid dosing for breakthrough pain. There were no serious adverse events related to Trichomylin softgel capsules, and the product was generally well tolerated.

"While the data remains early, the signals we are seeing reinforce our belief that Trichomylin softgel capsules have the potential to address cancer-related pain through a non-opioid alternative and support our continued efforts to generate robust clinical evidence," said Brent Zettl, CEO of ZYUS.